EUVIMEDEUVIMED entdecken
Crossref

Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial

James L Januzzi iD, Reza Mohebi, Yuxi Liu, Naveed Sattar iD, Hiddo J L Heerspink iD, Eshetu Tefera, Muthiah Vaduganathan iD, Javed Butler iD, Yshai Yavin, Jingwei Li, Carol A Pollock iD, Vlado Perkovic iD und 2 weitere

Circulation · 22.08.2023 · 148 (8) · 651-660

DOI: 10.1161/circulationaha.123.065251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Circulation, erschienen am 22.08.2023. Verfasst von James L Januzzi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (J.L.J., R.M., Y.L.). Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: People with type 2 diabetes and albuminuria are at an elevated risk for cardiac and renal events. The optimal biomarkers to aid disease prediction and to understand the benefits of sodium-glucose cotransporter-2 inhibition remain unclear. METHODS: Among 2627 study participants in the CREDENCE trial (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation), concentrations of NT-proBNP (N-terminal pro-B-type natriuretic peptide), high-sensitivity cardiac troponin T, growth differentiation factor-15, and IGFBP7 (insulin-like growth factor binding protein 7) were measured. The effect of canagliflozin on biomarker concentrations was evaluated. The prognostic potential of each biomarker on the primary outcome (a composite of end-stage kidney disease [dialysis, transplantation, or a sustained estimated glomerular filtration rate of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic NephropathiesDiabetes Mellitus, Type 2HumansCanagliflozinAlbuminuriaTroponin TBiomarkersGrowth Differentiation Factors

Stichwörter der Autor:innen

albuminuriabiomarkerscanagliflozindiabetes mellitusrenal insufficiency, chronic

Substanzen

CanagliflozinTroponin TBiomarkersGrowth Differentiation Factors

Autor:innen und Institutionen

  • Cardiology Division, Massachusetts General Hospital and Harvard Medical School, Boston (J.L.J., R.M., Y.L.).
  • Heart Failure and Biomarker Trials, Baim Institute for Clinical Research, Boston, MA (J.L.J.).
  • BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK (N.S.).
  • Department Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, the Netherlands (H.J.L.H.).
  • Janssen Research & Development, LLC, Spring House, PA (E.T., Y.Y., M.K.H.).
  • Cardiology Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA (M.V.).

ORCID-Profile: James L Januzzi, Naveed Sattar, Hiddo J L Heerspink, Muthiah Vaduganathan, Javed Butler, Carol A Pollock, Vlado Perkovic, Bruce Neal, Michael K Hansen

Zitieren

APA

Januzzi, J. L., Mohebi, R., Liu, Y., Sattar, N., Heerspink, H. J. L., Tefera, E., Vaduganathan, M., Butler, J., Yavin, Y., Li, J., Pollock, C. A., Perkovic, V., Neal, B., & Hansen, M. K. (2023). Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Circulation, 148(8), 651-660. https://doi.org/10.1161/circulationaha.123.065251

Vancouver

Januzzi JL, Mohebi R, Liu Y, Sattar N, Heerspink HJL, Tefera E, et al. Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial. Circulation. 2023;148(8):651-660. doi:10.1161/circulationaha.123.065251

BibTeX
@article{Januzzi2023,
  author = {Januzzi, James L and Mohebi, Reza and Liu, Yuxi and Sattar, Naveed and Heerspink, Hiddo J L and Tefera, Eshetu and Vaduganathan, Muthiah and Butler, Javed and Yavin, Yshai and Li, Jingwei and Pollock, Carol A and Perkovic, Vlado and Neal, Bruce and Hansen, Michael K},
  title = {Cardiorenal Biomarkers, Canagliflozin, and Outcomes in Diabetic Kidney Disease: The CREDENCE Trial},
  journal = {Circulation},
  year = {2023},
  volume = {148},
  number = {8},
  pages = {651--660},
  doi = {10.1161/circulationaha.123.065251}
}
Kostenlos starten →